S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Adamis Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:ADMP)

$1.26
+0.19 (+17.76 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$1.06
Now: $1.26
$1.44
50-Day Range
$0.50
MA: $0.73
$1.09
52-Week Range
$0.48
Now: $1.26
$3.29
Volume5.00 million shs
Average Volume752,318 shs
Market Capitalization$77.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.09 million
Book Value$0.65 per share

Profitability

Net Income$-39,010,000.00
Net Margins-175.77%

Miscellaneous

Employees152
Market Cap$77.66 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive ADMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter.


Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions

What is Adamis Pharmaceuticals' stock symbol?

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.06. The specialty pharmaceutical company had revenue of $5.90 million for the quarter, compared to analyst estimates of $6.55 million. Adamis Pharmaceuticals had a negative return on equity of 90.00% and a negative net margin of 175.77%. View Adamis Pharmaceuticals' Earnings History.

When is Adamis Pharmaceuticals' next earnings date?

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Adamis Pharmaceuticals.

What price target have analysts set for ADMP?

4 equities research analysts have issued twelve-month price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.10 to $6.00. On average, they expect Adamis Pharmaceuticals' share price to reach $3.70 in the next year. This suggests a possible upside of 193.7% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

What is the consensus analysts' recommendation for Adamis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.

Has Adamis Pharmaceuticals been receiving favorable news coverage?

Media coverage about ADMP stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Adamis Pharmaceuticals.

Who are some of Adamis Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamis Pharmaceuticals own?

Who are Adamis Pharmaceuticals' key executives?

Adamis Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard C. Williams, Chairman & Consultant (Age 75)
  • Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
  • Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
  • Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
  • Mr. Robert B. Rothermel, Consultant & Director (Age 75)

Who are Adamis Pharmaceuticals' major shareholders?

Adamis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.14%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.

Which major investors are buying Adamis Pharmaceuticals stock?

ADMP stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Adamis Pharmaceuticals.

How do I buy shares of Adamis Pharmaceuticals?

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals' stock price today?

One share of ADMP stock can currently be purchased for approximately $1.26.

How big of a company is Adamis Pharmaceuticals?

Adamis Pharmaceuticals has a market capitalization of $77.66 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

What is Adamis Pharmaceuticals' official website?

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

How can I contact Adamis Pharmaceuticals?

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]


MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel